The YODA Project
Research Proposal Due Diligence Assessment

Part 1: General Information	
YODA Project (Protocol) ID:	2020-4175
Date:	21 February 2020
Product Name:	Risperidone/ Paliperidone/ Paliperidone palmitate
Therapeutic Area:	Neuroscience
Product Class:	atypical antipsychotics
Condition(s) Studied:	Schizophrenia
Protocol Number(s) and Title(s):	**Paliperidone/ palmitate:** NCT00086320 R076477-SCH-301 NCT00645307 R076477-SCH-701 NCT01662310 R076477-SCH-3041 NCT00111189 R092670PSY3001 NCT01529515 R092670PSY3012 NCT01193153 R092670SCA3004 **Risperidone:** NCT00378092 RISSCH3024

Part 2: Data Availability	
Question:	**Response:**
Data Holder has authority to provide clinical trial data or development partner has agreed to share clinical trial data.	Yes
Comments: N/A	
Data Holder has sharable electronic clinical trial data or data can be converted to electronic format.	Yes
Comments: N/A	
De-identification and redaction of clinical trial data in accordance with current HIPAA and EU criteria allows protection of participant privacy and confidentiality.	Yes
Comments: N/A	
The product and relevant indication studied has either been approved by regulators in the US and EU, or terminated from development.	Yes
Comments: N/A	
Data Holder has completed the clinical trial and trial has been completed for a period of at least 18 months (or results published in peer-reviewed biomedical literature).	Yes
Comments: N/A	

Part 3: Data Availability Summary	
Based on the responses to the above Data Availability questions, the requested clinical trial data can be made available for data sharing.	Yes

Part 4: Proposal Review	
Question:	**Response:**
Summary-level CSR data is appropriate for the proposed analysis.	No
Participant-level data is appropriate for the proposed analysis.	Yes
A similar analysis is underway or completed/pending disclosure by Janssen.	No
Comments:	